PainReform Ltd (NASDAQ: PRFX)’s stock price has decreased by -1.82 compared to its previous closing price of 2.75. However, the company has seen a -15.62% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-20 that TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research (“Lotus”), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
Is It Worth Investing in PainReform Ltd (NASDAQ: PRFX) Right Now?
The stock has a 36-month beta value of 0.71. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRFX is 0.56M, and at present, short sellers hold a 5.20% of that float. On November 29, 2024, the average trading volume of PRFX was 906.77K shares.
PRFX’s Market Performance
The stock of PainReform Ltd (PRFX) has seen a -15.62% decrease in the past week, with a 16.18% rise in the past month, and a -49.55% fall in the past quarter. The volatility ratio for the week is 21.72%, and the volatility levels for the past 30 days are at 18.99% for PRFX. The simple moving average for the past 20 days is 2.39% for PRFX’s stock, with a -83.69% simple moving average for the past 200 days.
PRFX Trading at 4.12% from the 50-Day Moving Average
After a stumble in the market that brought PRFX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.65% of loss for the given period.
Volatility was left at 18.99%, however, over the last 30 days, the volatility rate increased by 21.72%, as shares surge +33.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.30% lower at present.
During the last 5 trading sessions, PRFX fell by -16.56%, which changed the moving average for the period of 200-days by -94.73% in comparison to the 20-day moving average, which settled at $2.64. In addition, PainReform Ltd saw -95.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRFX
Current profitability levels for the company are sitting at:
- -1747572045538315.2 for the present operating margin
- -1666595129258.69 for the gross margin
The net margin for PainReform Ltd stands at -1732572689374994.2. The total capital return value is set at 9.99. Equity return is now at value -716.67, with -309.43 for asset returns.
Currently, EBITDA for the company is -9.57 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of -110714561381807.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.61.
Conclusion
To sum up, PainReform Ltd (PRFX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
